Last reviewed · How we verify

NCT04688190: CHOICE-MI

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

Recruiting now Last updated 17 May 2022
What this trial tests

trial in Mitral Regurgitation in 800 participants. Currently enrolling.

Timeline
1 November 2020
Primary endpoint
1 March 2025
31 December 2030

Quick facts

Lead sponsorUniversitätsklinikum Hamburg-Eppendorf
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment800
Start date1 November 2020
Primary completion1 March 2025
Estimated completion31 December 2030
Sites26 locations across Denmark, France, Italy, United Kingdom, Germany, Norway, Canada, Switzerland

Conditions studied

Sponsor

Universitätsklinikum Hamburg-Eppendorf — full company profile →

Who can join

18 and older, any sex, with Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry.
    Ludwig S, Perrin N, Coisne A, Ben Ali W, et al · · 2023 · cited 27× · PMID 37235388 · DOI 10.4244/eij-d-22-01037
  2. Transcatheter Mitral Valve Replacement Versus Medical Therapy for Secondary Mitral Regurgitation: A Propensity Score-Matched Comparison.
    Ludwig S, Conradi L, Cohen DJ, Coisne A, et al · · 2023 · cited 15× · PMID 37194288 · DOI 10.1161/circinterventions.123.013045
  3. Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification.
    Coisne A, Ludwig S, Scotti A, Ben Ali W, et al · · 2024 · cited 14× · PMID 39243262 · DOI 10.1016/j.jcin.2024.07.038
  4. Management of patients with mitral regurgitation ineligible for standard therapy undergoing TMVI screening.
    Ludwig S, Sedighian R, Weimann J, Koell B, et al · · 2022 · cited 11× · PMID 34992049 · DOI 10.4244/eij-d-21-00708
  5. Challenges and Open Issues in Transcatheter Mitral Valve Implantation: Smooth Seas Do Not Make Skillful Sailors.
    Russo G, Maisano F, Massaro G, Terlizzese G, et al · · 2021 · cited 8× · PMID 35224022 · DOI 10.3389/fcvm.2021.738756
  6. Phenotypic clustering analysis of patients rejected for mitral valve interventions: implications for future transcatheter technologies.
    Ludwig S, Coisne A, Hamzi K, Ben Ali W, et al · · 2025 · cited 2× · PMID 40329826 · DOI 10.1093/ehjci/jeaf141

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

Other Universitätsklinikum Hamburg-Eppendorf trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04688190.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing